Skip to main content

Share story

Science

Phase-one mesothelioma study reports PRX3 inhibitor results

Phase-one mesothelioma study reports PRX3 inhibitor results Image: Primary
Researchers at the University of Vermont and collaborators reported phase-one results for RSO-021, a clinical formulation of thiostrepton, in relapsed mesothelioma. In 15 patients, the trial controlled disease progression in 67%; average progression-free survival was 4.2 months, roughly comparable with existing treatments. The treatment blocks PRX3, causing hydrogen peroxide to build up in tumor-cell mitochondria. The phase-one trial was conducted in the UK between 2022 and 2023, and phase two has since been completed; results are expected to be presented this year.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from All Top News -- ScienceDaily and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
AI Capital
AI Capital

Lumaril raises $66 million for industrial AI software

Lumaril raised a $66 million Series A at a $400 million valuation, The Wall Street Journal reported. The company develops AI software that connects to manufacturers' existing control systems to optimize industrial production on factory floors.

AI Science
AI Science

Harvard smartphone navigation app reduces collisions in 14-person test

Harvard researchers reported that 14 test subjects using their Mobilio smartphone app with a cane reached destinations 13% faster and had 41% fewer indoor collisions than people using a cane with Google Maps. The findings appear in Nature Biomedical Engineering.

Security
Security

Binance plans phased withdrawal restart after hack

Binance says it plans to resume withdrawals in phases starting Sunday after covering 95% of the $6.3 billion in tokens stolen in a hack, Reuters reports. The stolen tokens included BTC and ETH. The planned restart would restore withdrawal access in stages.